Liminal BioSciences, Inc.
(NASDAQ : LMNL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.73%69.000.0%$2156.62m
NVAXNovavax, Inc. 7.83%143.7196.5%$1221.19m
SRNESorrento Therapeutics, Inc. -4.46%12.432.8%$767.17m
GILDGilead Sciences, Inc. 0.40%68.451.0%$570.20m
AMGNAmgen, Inc. 0.22%239.391.3%$469.60m
REGNRegeneron Pharmaceuticals, Inc. 0.27%612.522.7%$385.80m
VRTXVertex Pharmaceuticals, Inc. -0.19%266.661.9%$352.51m
BIIBBiogen, Inc. 0.41%289.741.6%$351.56m
BNTXBioNTech SE -2.00%69.580.0%$345.97m
ILMNIllumina, Inc. -2.46%344.843.5%$343.12m
ATNMActinium Pharmaceuticals, Inc. -0.61%9.8513.3%$235.18m
VXRTVaxart, Inc. 0.55%9.140.0%$213.40m
EBSEmergent BioSolutions, Inc. -1.37%133.096.4%$196.68m
MCRBSeres Therapeutics, Inc. -3.20%27.673.6%$180.94m
ALXNAlexion Pharmaceuticals, Inc. 0.92%102.832.0%$164.58m

Company Profile

Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.